Cassava Starts Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s

 

• 804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical Trial
• A Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately 1,100 Patients.

https://www.biospace.com/article/releases/cassava-sciences-completes-patient-enrollment-for-pivotal-phase-3-clinical-trial-of-oral-simufilam-in-alzheimer-s-disease/